Back to Trades
Grant4
BOSTON SCIENTIFIC CORP
BSX
Total Value
$11.1M
Company Information
- Company Name
- BOSTON SCIENTIFIC CORP
- Ticker Symbol
- BSX
- CIK
- 0000885725
Insider Information
- Role
- Chairman, President & CEO, Director
- Location
- MARLBOROUGH, MA
DirectorOfficer
Filing Details
- Filing Date
- Feb 18, 2026
- Transaction Date
- Feb 13, 2026
- Accession Number
- 0001225208-26-002135
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Feb 13, 2026 | Common Stock | 132,190 | — | Grant/Award | — |
| Feb 13, 2026 | Common Stock | 132,190 | — | Grant/Award | — |
| Feb 13, 2026 | Common Stock | 8,832 | — | Exercise | — |
| Feb 13, 2026 | Common Stock | 132,099 | $74.73 | Tax Withholding | $9.9M |
| Feb 14, 2026 | Common Stock | 16,524 | — | Exercise | — |
| Feb 14, 2026 | Common Stock | 7,990 | $74.73 | Tax Withholding | $597.1K |
| Feb 16, 2026 | Common Stock | 16,265 | — | Exercise | — |
| Feb 16, 2026 | Common Stock | 7,865 | $74.73 | Tax Withholding | $587.8K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Feb 13, 2026 | Derivative | 8,832 | — | Exercise | — |
| Feb 14, 2026 | Derivative | 16,524 | — | Exercise | — |
| Feb 16, 2026 | Derivative | 16,265 | — | Exercise | — |
Footnotes
- (F1)On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- (F2)On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- (F3)Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- (F4)Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
- (F5)Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
- (F6)Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.